Pancreatic cancer chemo trial pulled before it started

NCT ID NCT05415917

Terminated Disease control Sponsor: Rutgers, The State University of New Jersey Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study was designed to see if giving two chemotherapy drugs (gemcitabine and capecitabine) after surgery could help people with pancreatic cancer stay cancer-free longer. It was for patients who had already received chemotherapy before surgery. However, the trial was withdrawn before enrolling any participants, so no data was collected.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: gemcitabine and capecitabine (chemotherapy)
What this could lead to: If successful, this could show that additional chemotherapy after surgery improves disease-free survival for pancreatic cancer patients who already had pre-surgery treatment.
What could go wrong: The trial was withdrawn before enrolling anyone, so no results are available. Chemotherapy can cause significant side effects like low blood counts and fatigue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.